Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for B2W0S3

Entry ID Method Resolution Chain Position Source
AF-B2W0S3-F1 Predicted AlphaFoldDB

No variants for B2W0S3

Variant ID(s) Position Change Description Diseaes Association Provenance
No variants for B2W0S3

2 associated diseases with B2W0S3

[MIM: 608971]: Severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID)

A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. {ECO:0000269|PubMed:11145714}. Note=The disease is caused by variants affecting the gene represented in this entry.

[MIM: 126200]: Multiple sclerosis (MS)

A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease. {ECO:0000269|PubMed:11101853}. Note=Disease susceptibility may be associated with variants affecting the gene represented in this entry.

Without disease ID
  • A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. {ECO:0000269|PubMed:11145714}. Note=The disease is caused by variants affecting the gene represented in this entry.
  • A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease. {ECO:0000269|PubMed:11101853}. Note=Disease susceptibility may be associated with variants affecting the gene represented in this entry.

10 regional properties for B2W0S3

Type Name Position InterPro Accession
domain Tyrosine-specific protein phosphatase, PTPase domain 652 - 914 IPR000242-1
domain Tyrosine-specific protein phosphatase, PTPase domain 943 - 1230 IPR000242-2
domain Tyrosine-specific protein phosphatases domain 832 - 903 IPR000387-1
domain Tyrosine-specific protein phosphatases domain 1135 - 1219 IPR000387-2
domain Protein-tyrosine phosphatase, catalytic 810 - 911 IPR003595-1
domain Protein-tyrosine phosphatase, catalytic 1116 - 1227 IPR003595-2
domain Fibronectin type III 391 - 483 IPR003961-1
domain Fibronectin type III 484 - 576 IPR003961-2
active_site Protein-tyrosine phosphatase, active site 851 - 861 IPR016130
domain Protein tyrosine phosphatase, receptor type, N-terminal 7 - 32 IPR024739

Functions

Description
EC Number
Subcellular Localization
  • Vacuole membrane ; Multi-pass membrane protein
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

2 GO annotations of cellular component

Name Definition
integral component of membrane The component of a membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane.
vacuolar membrane The lipid bilayer surrounding the vacuole and separating its contents from the cytoplasm of the cell.

2 GO annotations of molecular function

Name Definition
metal ion binding Binding to a metal ion.
metalloexopeptidase activity Catalysis of the hydrolysis of a peptide bond not more than three residues from the N- or C-terminus of a polypeptide chain by a mechanism in which water acts as a nucleophile, one or two metal ions hold the water molecule in place, and charged amino acid side chains are ligands for the metal ions.

1 GO annotations of biological process

Name Definition
proteolysis The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds.

No homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
No homologous proteins
10 20 30 40 50 60
MARYNPFSFT PGPVVFFTTV IYVGLFAALL VTHLTVPDYP SDPPAGINLT EAWADLEHIT
70 80 90 100 110 120
RRFHPYNSHA NDHVRGYLLS RIQGVIATKA LDASQVEVID DLTSNATFSS GATSVYFEGT
130 140 150 160 170 180
NIIVVIRGSE DDEPFNSTDR KPNNGGVLVN AHYDSVSSGY GATDDGVGVV TVLQLLSYFT
190 200 210 220 230 240
ESHNWPKRTI ILLLNNGEED FLNGAKAFMR NPISQVPHTF VNLEGAGAGG RATLFRSTDT
250 260 270 280 290 300
EVTRFYSKSK YPFGTVVSGD GFKKGLIRSE TDYRVFHGEL GLRGLDIAFM EPRARYHTVE
310 320 330 340 350 360
DSTRETSMNS LWHMLSAALA STSGLAAVTG EEFSGSESLD NGRVNAGRGS DGVWFDLFGR
370 380 390 400 410 420
VFVVFQLHTL FALCVTLLVV APIALIGLTF GLSKADKNYL LARKAFVYSS DDDNPVQLYG
430 440 450 460 470 480
WRGFFRFPIV FVSATAVVVA LAYLLVRFNA FIIYSSPFAV WSMMLSAWFF VAWFFSRGAD
490 500 510 520 530 540
AMRPSALQRM YALIWLFIGS FVLLTIITVF VNNYQVVAGY PALFYFAVVF AALMLSYLEL
550 560 570 580 590 600
FFAPTKSAYA RHFEHDTSSR RNSESASRPL TGSTTAARSD DRPVADDDAT ETTSLLRGDR
610 620 630 640 650 660
RGFTRYGSRR DSTSEGDEDH AQGSRRLDLG NVYPGEQEWS GKLPSWIWII QLLLLAPLVI
670 680 690 700 710 720
VLVGQVALLL TSALYQTPSD GNSPLFIYLA IAALSVLLLA PTGPFIHRFT YHVPTFLFLV
730 740 750 760 770 780
CLATVIYNLV AFPFSRDHRL KVYFVQRVNC ETGANTVSLT GLDSYVQRIV GELPSAQDQP
790 800 810 820 830 840
LNCTTPDVAT RKELKTCEWE GLPAKVVPNA AGAAPFGNET NTDRWLEYSI HKGNRSNKAT
850 860 870 880 890 900
IRVVGLNTRA CRIVFDSPIT GLAVTGAVSD PRFKPVGAAG SREVRLWHRE FGQPWNVALT
910 920 930 940 950
WDAEEHAKLS GRVVCLWSDA NTGSIPAFDE VQHYLPVWAI PSKISDGLVE GFKQFEI